Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2Lung Neoplasms 1

Interventions

Carboplatin 341Paclitaxel 262Cisplatin 233Pemetrexed 226Docetaxel 206Erlotinib Hydrochloride 193Gemcitabine 178pembrolizumab 137Bevacizumab 121Radiotherapy 118Nivolumab 84Gefitinib 73Vinorelbine 64Cetuximab 58atezolizumab 47Afatinib 46durvalumab 44osimertinib 41Radiosurgery 35Ipilimumab 34Drug Therapy 32Taxes 30Albumin-Bound Paclitaxel 29130-nm albumin-bound paclitaxel 29Surgical Procedures, Operative 28Etoposide 25Irinotecan 24Sorafenib 21Cyclophosphamide 20Radiation 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Carcinoma, Non-Small-Cell Lung × talactoferrin alfa × Clear all
NCT00923741 2018-07-05

Effect of Talactoferrin in Adults With Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
10 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00707304 2012-08-21

FORTIS-M

Agennix

Phase 3 Completed
742 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡